Verastem, Inc. Files 8-K Report
Ticker: VSTM · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1526119
| Field | Detail |
|---|---|
| Company | Verastem, INC. (VSTM) |
| Form Type | 8-K |
| Filed Date | Oct 23, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, financials
TL;DR
Verastem filed an 8-K, mostly boilerplate but could have news.
AI Summary
On October 23, 2025, Verastem, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Verastem, Inc. is providing updated information to the SEC, which could include material disclosures relevant to investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification without specific material events or financial data that would indicate immediate risk.
Key Players & Entities
- Verastem, Inc. (company) — Registrant
- October 23, 2025 (date) — Date of earliest event reported
- 117 Kendrick Street, Suite 500, Needham, MA 02494 (address) — Principal Executive Offices
- 273269467 (ein) — IRS Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing for Verastem, Inc.?
The filing is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on October 23, 2025.
What is Verastem, Inc.'s principal executive office address?
The principal executive offices are located at 117 Kendrick Street, Suite 500, Needham, MA 02494.
What is Verastem, Inc.'s telephone number?
The company's telephone number, including area code, is (781) 292-4200.
Under which state was Verastem, Inc. incorporated?
Verastem, Inc. was incorporated in Delaware.
Filing Stats: 1,038 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2025-10-23 16:02:05
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share VSTM The Nasdaq
Filing Documents
- tm2529362d1_8k.htm (8-K) — 30KB
- tm2529362d1_ex99-1.htm (EX-99.1) — 20KB
- 0001104659-25-101817.txt ( ) — 220KB
- vstm-20251023.xsd (EX-101.SCH) — 3KB
- vstm-20251023_lab.xml (EX-101.LAB) — 33KB
- vstm-20251023_pre.xml (EX-101.PRE) — 22KB
- tm2529362d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 23, 2025, Verastem, Inc. (the "Company") issued a press release announcing preliminary data from the first two dose levels from the VS-7375 Phase 1/2a dose escalation trial in patients with KRAS G12D mutant solid tumors. A copy of this press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K.
01 Other Events
Item 8.01 Other Events Recent Developments Updated Data from VS-7375 Phase 1/2a Dose Escalation Trial of VS-7375 in Patients with KRAS G12D Mutant Solid Tumors The Company reported preliminary data from the first two dose levels in its ongoing Phase 1/2a clinical trial evaluating the safety and efficacy of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors, including advanced pancreatic ductal adenocarcinoma ("PDAC") both as monotherapy and in combination with other standard of care treatments. In the study, VS-7375 cleared both the 400 mg daily ("QD") and 600 mg QD monotherapy doses with no dose-limiting toxicities ("DLTs") observed. The safety profile in PDAC and non-small cell lung cancer ("NSCLC") patients was consistent with the previously reported data at recent medical congresses by the Company's partner GenFleet Therapeutics ("Genfleet") in its ongoing Phase 1 /2 clinical study in China evaluating VS-7375 (known as GFH375). Specifically, at the two dose levels evaluated in the U.S. cohorts, no nausea, diarrhea or vomiting greater than Grade 1 were reported. Monotherapy dose escalation in the VS-7375-101 study started at the efficacious doses identified in GenFleet's study, 400 mg QD and 600 mg QD. GenFleet chose 600 mg QD as their recommended Phase 2 dose in China. Of the five efficacy evaluable patients in the VS-7375-101 study, with at least one scan, four out of five patients have had a tumor reduction and are still on treatment. The remaining patients receiving either the 400 mg QD or 600 mg QD doses have not yet reached their first response assessment. In addition, while monotherapy dose escalation continues, the Company announced it has initiated patient enrollment for the first dose escalation combination cohort evaluating VS-7375 with cetuximab. The cohort is expected to enroll patients with advanced solid tumors, including colorectal cancer.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release, dated October 23, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: October 23, 2025 By: /s/ Daniel W. Paterson Daniel W. Paterson Chief Executive Officer